Multizentrische, randomisierte, doppelblinde, Placebo kontrollierte Induktionsstudie zur Beurteilung der Wirksamkeit und Sicherheit von Risankizumab bei Patienten mit mittelschwerem bis schwerem aktivem Morbus Crohn, die auf eine vorhergehende Therapie mit Biologika nicht angesprochen haben

Drug: placebo for risankizumab IV;Drug: risankizumab SC;Drug: risankizumab IV

Inclusion Criteria:

- Male or female aged >=18 to <= 80 years, or minimum age of adult consent according to
local regulations, at the Baseline Visit. Where locally permissible, participants 16
to < 18 years of age who meet the definition of Tanner stage 5 for development at the
Baseline Visit.

- Confirmed diagnosis of CD for at least 3 months prior to Baseline.

- Crohn's disease activity index (CDAI) score 220 - 450 at Baseline.

- Confirmed diagnosis of moderate to severe CD as assessed by stool frequency (SF),
abdominal pain (AP) score, and Simple Endoscopic Score for Crohn's Disease (SES-CD).

- Demonstrated intolerance or inadequate response to biologic therapy for CD.

- If female, participant must meet the contraception recommendations.

Exclusion Criteria:

- Participant with a current diagnosis of ulcerative colitis or indeterminate colitis.

- Participants with unstable doses of concomitant Crohn's disease therapy.

- Receipt of Crohn's disease approved biologic agents (infliximab, adalimumab,
certolizumab, vedolizumab, natalizumab within 8 weeks prior to Baseline or ustekinumab
within 12 weeks prior to Baseline), or any investigational biologic or other agent or
procedure within minimally 35 days or 5 half-lives prior to Baseline, whichever is
longer.

- Prior exposure to p19 inhibitors (e.g., risankizumab).

- Complications of Crohn's disease.

- Having an ostomy or ileoanal pouch.

- Known active Coronavirus Disease 2019 (COVID-19) infection.